Cambridge Healthtech Institute’s 3rd Annual

Targeting NASH

Drug Development for Inflammation and Fibrosis of the Fatty Liver 

September 17-18, 2019


Non-alcoholic steatohepatitis (NASH) is a disease whose incidence is rising and is related to an accumulation of fat in the liver that can lead to its disfunction due to excessive inflammation and fibrosis. No medical treatments yet exist for NASH but it’s a hopeful  time for the field because several drug candidates are in phase 2 and 3 clinical trials. New NASH drug targets are also being revealed due to progress in the fields of NASH contributors: metabolic disfunction, inflammation and fibrosis. Significant challenges remain however such as the need for non-invasive biomarkers and better models for the disease. At Cambridge Healthtech Institute's Targeting NASH conference, join academic and industry investigators to learn and discuss with one another drug development progress, challenges and solutions in the arena of treating fatty liver disease. 


This NASH conference will be followed by a 1.5 day conference on the related topic of Fibrosis at the same Discovery on Target event.


Who should attend: Heads of Research Departments, Directors, Chief Scientific Officers, Professors, Post-doctoral Research Fellows, Graduate Students, Principal Scientists, Senior Scientists, Discovery Biologists, Discovery Chemists, Immunologists, Pharmacologists; in departments such as liver disease research, autoimmunity, inflammation, immunology, metabolism, diabetes.  


Coverage will include, but is not limited to:                                        

  • Progress on drug candidates targeting nuclear hormone receptors: PPARs, FXR agonsits
  • Thyroid receptor hormone agonists
  • Galectin-targeted drug candidates
  • Compounds in late stage discovery or early development against new NASH targets
  • NASH drug candidates in early clinical trials 
  • Metabolic disease targets being investigated as potential NASH targets, e.g., GLP1
  • New models for liver disease including induced pluripotent stem cells (iPS) 
  • Potential non-invasive NASH biomarkers

If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is February 27, 2019.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286


Premier Sponsors

Ablexis Alivamab_stacked



OmniAb Ligand_Pharmaceuticals